ALKERMES | ALKS - Operating Profit

Stock Price
32.26
Daily Change
0.35 1.10%
Monthly
-2.57%
Yearly
-9.18%
Q1 Forecast
30.94

ALKERMES reported $89.08M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Coherus Biosciences USD -45.43M 3.13M Mar/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Heron Therapeutics USD -5.66M 782K Sep/2024
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Malin Corporation EUR -1.1M 400K Dec/2024
Merck USD 6.24B 318M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Otsuka Holdings JPY 67.25B 101.57B Dec/2025
Ovoca Bio EUR -5.65M 3.45M Jun/2022
Pfizer USD 4.65B 3.99B Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025